MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic
Clinical and Translational Oncology · 10.08.2026
DOI: 10.1007/s12094-026-04529-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 10.08.2026. Verfasst von Fábio França Vieira E Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Abramo Lincoln, 5, 81100, Caserta, Italy. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: MutL homolog 1 (MLH1) is a key component of the mismatch repair (MMR) pathway, and promoter methylation-mediated silencing is a well-established oncogenic mechanism in several tumor types. However, its prevalence and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC) remain unclear. METHODS: We retrospectively analyzed 55 patients with PDAC diagnosed between 2012 and 2021 at a tertiary center. MLH1 promoter methylation (%) was quantified by pyrosequencing in formalin-fixed, paraffin-embedded tumor samples and classified using predefined (8%) and exploratory ROC-derived (2.6%) cut-offs. Associations with clinicopathological variables and disease-specific survival (DSS) were assessed using Cox regression models, with additional exploratory quartile-based and cubic spline analyses. External validation was performed using multi-omics data from The Cancer Genome Atlas Pancreatic Adenocarcinoma (TCGA-PAAD) cohort. RESULTS: MLH1 promoter methylation levels varied widely (mean 11.3%, range 2.0-42.2%) with 41.8% and 74.5% of cases classified as methylated using the predefined and exploratory cut-offs, respectively. No significant associations were observed with clinicopathological variables. In multivariable analysis, MLH1 methylation was not associated with DSS at either cut-off (HR = 1.55, 95% CI 0.85-2.85, p = 0.153; HR = 1.31, 95% CI 0.66-2.62, p = 0.442). Quartile-based and cubic spline analyses did not identify threshold-dependent or non-linear associations with DSS. In TCGA-PAAD data, neither MLH1 methylation nor gene expression correlated with overall survival, whereas low MLH1 protein expression was associated with worse outcomes. CONCLUSION: Although MLH1 promoter methylation is frequent in PDAC, it was not associated with DSS. These findings suggest limited prognostic value of MLH1 promoter methylation alone and support the integration of functional and multi-layered molecular data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via Abramo Lincoln, 5, 81100, Caserta, Italy.
- Department of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Galician Healthcare Service (SERGAS), University of Santiago de Compostela, Ch…
- Department of Clinical and Experimental Medicine, University of Foggia, Via Napoli, 20, 71122, Foggia, Italy.
- Human Anatomy and Embryology Area, Department of Functional Biology and Health Sciences, University of Vigo, Lagoas-Marcosende, S/N, 36310, Vigo, Spain.
Zitieren
APA
Silva, F. F. V. E., Di Domenico, M., Prada-Ramallal, G., Suárez-Peñaranda, J. M., Ballini, A., & Padín-Iruegas, M. E. (2026). MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04529-9
Vancouver
Silva FFVE, Di Domenico M, Prada-Ramallal G, Suárez-Peñaranda JM, Ballini A, Padín-Iruegas ME. MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04529-9
BibTeX
@article{Silva2026,
author = {Silva, Fábio França Vieira E and Di Domenico, Marina and Prada-Ramallal, Guillermo and Suárez-Peñaranda, José Manuel and Ballini, Andrea and Padín-Iruegas, María Elena},
title = {MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic},
journal = {Clinical and Translational Oncology},
year = {2026},
doi = {10.1007/s12094-026-04529-9}
}
EUVIMED